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1. Introduction
Worldwide there are an estimated 130 million people infected with
hepatitis C (HCV), 40 million living with HIV, and between 4 and 5 mil-
lion co-infected with HIV and HCV (Alter, 2006; Perz, Farrington,
Pecoraro, Hutin, & Armstrong, 2004; WHO. AIDS epidemic update,
2004). In Western Europe and the United States, co-infection tends to
concentrate among people who inject drugs (PWID) mainly driven by
blood contained in shared syringes and contaminated injection equip-
ment (Hahn, Page-Schafer, Lum, et al., 2002; Doerrbecker, Behrendt,
Matheu-Gelabert et al., 2013). Epidemiological data shows wide
discrepancies in HIV/HCV prevalence among PWID across the world
(Bao & Li, 2009; Rahimi-Movaghar, Razaghi, Sahim-Izadian, &
Amin-Esmaeili, 2010). In Western Europe some studies involving HIV
positive individuals with a history of injection drug use documented a
HIV/HCV co-infection rate of around 66%,while similar studies conduct-
ed on positive HIV patients who inject drugs enrolled in a large HIV clin-
ical trial showed that between 72%–95% were co-infected with HCV
(Denis et al., 1997; Roca et al., 2003; Sherman, Rouster, Chung, &
Rajicic, 2002; Sulkowski & Thomas, 2003).
N30 years after its identification, HIV/AIDS remains one of the most
serious public health problems in the United States and the world. The
concern is especially high in Puerto Rico, one of the U.S. island terri-
tories. In 2010, the rate of HIV infection diagnosis in Puerto Rico was
33.8 per 100.000 population, the fourth highest in the U.S., while the in-
fection rate for the U.S. as a whole was 19.7 (Centers for Disease Control
and Prevention, 2015). Further, the island's HIV death rate is nearly 4
times higher than the national average, higher than any other U.S.
state or territory (http://www.aidsunited.org/Programs-0024-
Grantmaking/Puerto-Rico.aspx, n.d). The most common HIV
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transmission method in Puerto Rico is injection drug use—42% of male
HIV cases are attributed to injection drug use, exactly double that of
the U.S. as a whole which attributes 21% of male HIV cases to injection
drug use. HCV has a prevalence among the general population on the is-
land of close to 2% (Perez, Marrero, Melendez, et al., 2010) but most
cases tend to concentrate in PWID where studies have shown a preva-
lence close to 90% in urban settings and 80% in rural areas (Reyes,
Colon, Robles, et al., 2006; Abadie, Welch-Lazoritz, Acosta-Gelpi,
Reyes, & Dombrowski, 2016).
Frequency of drug use, years of injection, using shooting galleries,
number of injection partners, along with sharing syringes and injection
equipment has been associated with a higher risk of HIV transmission
(Miller et al., 2002; Dolan et al., 2010; Rolls, Sacks-Davis, Jenkinson, et
al., 2013). While the social determinants of HIV transmission in PWID
have been extensively studied (Gilbert et al., 2013; Des Jarlais et al.,
2012; Travis et al., 2014), studies should be conducted specifically ad-
dressing the social determinants of HIV and HCV co-infection among
PWID in order to develop more targeted and effective prevention
strategies.
The current paper seeks to explore social and behavioral determi-
nants of HIV and HCV co-infection among PWID in rural areas of Puerto
Rico. A case study based on (n = 315) current intravenous drug users
shows that 6% of the population (n=19) is co-infectedwith both virus-
es. Co-infection correlates with age, longer period of drug use, medical
insurance coverage and sexual identity. A positive HIV diagnosis was
found to be a strong predictor of co-infection. No differences were
found in risk behaviors, both groups report similar frequencies of drug
use and sharing of needles and equipment but co-infected used report-
ed using a new syringe at a higher frequency that those who were not
co-infected.
2. Methods
2.1. Data
This paper utilizes data from 315 injection drug users residing in
Cidra, Comerio, Aguas Buenas, and Cayey, four rural towns in themoun-
tainous area of central Puerto Rico, about 30–40 miles from San Juan.
Sites were selected because they were representative of rural PWID on
the island (López, de Saxe Zerden, Bourgois, et al., 2015). In addition,
these sites were chosen due to the presence of El Punto en la Montaña,
the only syringe exchange program operating in rural Puerto Rico,
http://dx.doi.org/10.1016/j.abrep.2017.01.004
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withwhomweestablished a close collaboration that facilitated data col-
lection with this population. Interviews were completed between April
2015 and June 2015. Sample recruitment was managed using respon-
dent driven sampling (RDS) and we started two seeds in each of the
four towns (for a total of 8 seeds, 307 recruits). Participants who com-
pleted the survey were given three referral coupons to pass out to
other PWID they knew and who had not previously participated in the
study. Every eligible referral earned the recruiter an additional $10.
Upon completion of the questionnaire, participants were given $25.
RDS has proven effective in recruiting hard to reach populations
(Abdul-Quander et al., 2006; Heckathorn, 2002; Heckathorn, 2007;
Johnston, Chen, Silva-Santisteban, & Raymond, 2013; Cagle, Fisher,
Senter, & Thurmond, 2002). Participants were 18 years of age or older,
alert at the time of the interview, and active injection drug users
(injected drugs within the last 30 days). Verification of current injection
use was done through visual inspection of injection track marks as well
as through a questionnaire that measuring knowledge of injection prac-
tices (Fisher et al., 1993; Pouget, Hagan, & Des, 2012).
The questionnaire was interviewer-administered and based off of
the CDCNHBS IDU Round 3 Questionnaire version 13. In addition to de-
mographic variables, we collected information about type and frequen-
cy of drug use, as well as HIV and HCV risk behaviors such as sharing of
needles, cookers, cotton, and water in addition to sexual behaviors and
alcohol use. HIV and Hepatitis C status was assessed through the use of
INSTI Rapid HIV antibody tests (Biolytical Laboratories) and OraQuick
HCV Rapid antibody tests (OraSure Technologies). Every participant
was compensated an additional $5 for each rapid test performed. Partic-
ipants who tested positive for HCV or HIV were offered referral and
transportation to a primary care doctor for confirmatory testing. The
study received IRB approval through the University of Nebraska-Lincoln
(IRB# 20131113844FB) and the University of Puerto Rico School of
Medicine (IRB# A8480115).
2.2. Measures
Agewas calculated by subtracting the date of the interview from the
participant's date of birth.HIV status andHCV statuswere determined by
the results of the INSTI Rapid HIV and OraQuick Rapid HCV test. Mean
number of years injectingwas calculated by subtracting the age a partic-
ipant reported first injecting drugs by their age at the time of interview.
The gay, lesbian, or bisexual item includes participants who reported
identifying as gay, lesbian, or bisexual (1) compared to those who re-
ported identifying as straight or heterosexual. Annual per capita income
was assessed by two questionnaire items, onewhichparticipants select-
ed an income bracket and a second which participants reported how
many people rely on that income during the year. The upper limit of
the income bracket was then divided by the number of people relying
on income to achieve an approximation of annual per capita income.
Graduated High School or higher includes participants who reported
graduating from high school (1), completing a GED equivalent, or
higher (including some college, college graduates, and those with
post-graduate education) and those who did not graduate/obtain a
GED (0). Born in Puerto Ricomeasures whether participants were born
on the island of Puerto Rico (1) or somewhere else (0). Graduated
High School or higher includes participants who reported graduating
fromhigh school (1), completing a GED equivalent, or higher (including
some college, college graduates, and those with post-graduate educa-
tion) and those who did not graduate/obtain a GED (0). Born in Puerto
Ricomeasures whether participants were born on the island of Puerto
Rico (1) or somewhere else (0). Percent Homeless in the past year was
assessed using a question that asked participants whether they had ex-
perienced homelessness within the past year and currently homeless
used the question that asked whether participants were currently
homeless. Percent unemployed was assessed using a question that
asked participants which best described their employment status:
employed full time, employed part time, full time student, retired,
unable to work for health reasons, unemployed, or other. Participants
were given a (1) on the have health insurancemeasure if they reported
being covered by any type of health insurance, including state spon-
soredMedicare orMedicaid (Reforma in Puerto Rico), private health in-
surance, veterans health insurance, or some other type of health
insurance. Have a regular place for healthcare is based on the question
“is there a place that you usually go when you are sick or need advice
about your health?” and the follow up “what kind of place is it?”. Re-
sponses of yes (1) and a clinic, health center, or doctor's office were
coded as (1) while “no” not having a place was coded as (0), or yes
and reporting that that place is the emergency room was also coded
as (0).
Frequency of injectionwas assessed using the question “in the last 12
months, on average, how often did you inject drugs?” with response
choices of (1) one time per month, (2) 2–3 times per month, (3) one
time per week, (4) 2–6 times per week, (5) one time per day, (6) 2–3
times per day, and (7) 4 or more times per day. Frequency of (1) used
needle utilization, (2) used cooker utilization, (3) used cotton utilization,
(4) used water utilization, and (5) sterile needle utilization are five cate-
gorical measures asking how often, in the past year, the participant
used (1) needles that someone else had already injected with, (2) a
cooker that someone else had already used, (3) a cotton that someone
else had already used, (4) water that someone else had already used,
and (5) a new, sterile needle to inject. The response options are: never
(coded as 1), rarely (coded as 2), about half of the time (coded as 3),
most of the time (coded as 4), and always (coded as 5).
2.3. Analytic approach
The results reported in this analysis stem from t-tests (for continu-
ous variables) and ANOVA tests (for categorical or dichotomous vari-
ables) to compare HIV and HCV co-infected participants (n = 19)
with the remainder of the sample (n = 296). We are aware that the
very small sample size (n = 19) of the co-infected group likely limits
our statistically significant findings. All analyses were conducted using
IBM SPSS Statistics software.
3. Results
Exactly 19 participants (6.0% of the total sample) tested positive for
HIV antibodies. All of these individuals also tested positive for HCV anti-
bodies and are referred to as the co-infected group. Of the HIV+ partic-
ipants, 63.2% (n = 12) already knew that they were HIV+ prior to
participation in this study. The remaining 7 individuals were given an
HIV positive rapid test result, HIV counseling, and offered transporta-
tion/referral to a medical doctor for confirmatory testing and medical
care (though no individuals accepted this offer). Only 10 co-infected
participants were already aware of their hepatitis C positive status
prior to participation in this study, 8 of which found out they were
HCV+ over ten years ago. Of the 10 co-infected participants who had
known about their HCV status, only one had ever been treated for hep-
atitis C.
Table 1 includes demographic characteristics for the HIV/HCV co-in-
fected group and the remainder of the sample (not co-infected; 68 of
whom are both HIV− andHCV−, 228 are HCV+butHIV−). Co-infect-
ed participants were significantly older (49 years compared to 41 years;
p b 0.001) than PWIDwhowere not co-infected. Additionally, co-infect-
ed participants showed significantly different injection drug use histo-
ries than PWID with no co-infection. Co-infected individuals had been
injecting drugs for an average of 29.1 years, while their HIV− counter-
parts had been injecting for nearly a decade less (19.3 years; p b 0.000).
However, the current habits of both co-infected and HIV− participants
look similar. Both groups have about the same frequency of injection
and inject with used needles and “works” (cooker, cotton, or water)
that had been used first by someone else at about the same rate.
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However, co-infected participants injected with a new, sterile needle
significantly more often than their HIV− counterparts (p = 0.026).
Co-infected PWID were also significantly more likely to have health
insurance (100% compared to 81%; p b 0.000). This difference could be
driven by the co-infected participants who were aware of their status
prior to study participation. In addition,most (63.2%) co-infected partic-
ipants reported having a regular place to go for healthcare (not includ-
ing the emergency department), compared to only 41.4% of HIV−
individuals (p = 0.063). Both groups had similar gender proportions
(the co-infected group is made up of 17 males and 2 females), average
annual per capita incomes, and similar education levels. Co-infected
PWID in this sample were significantly more likely to report being
gay, lesbian, or bisexual (21.7% compared to 2.7%; p b 0.000) than
those who are uninfected or mono-infected. Of the co-infected individ-
uals who identified as gay, lesbian, or bisexual, one is female and three
are male.
A few other differences were observed, although were not found to
be statistically significant (also found in Table 1). A higher percentage
of co-infected individuals had been born on the island of Puerto Rico
(93.9% compared to 84.2%) than PWID whowere not co-infected. Addi-
tionally, a higher percentage of HIV/HCV co-infected individuals experi-
enced homelessness in the past year and were currently homeless than
those who were not co-infected. Unemployment was slightly more
prevalent among co-infected individuals as well.
4. Discussion
A positive HIV result strongly correlates with HCV co-infection. All
PWID who tested HIV positive in our sample, also produced HCV posi-
tive results. This result might be related to virological characteristics of
HCV which makes virus transmission risk higher than HIV. HCV has
been shown to be ten times more infectious than HIV and the virus
can live outside the body for many days (Paintsil, Binka, Patel,
Lindenbach, & Heimer, 2014; Paintsil, He, Peters, Lindenbach, &
Heimer, 2010; Thorpe et al., 2002). Those exposed to the HIV might
have been more likely to be also exposed to HCV mainly through con-
taminated syringes and injection equipment (Hagan et al., 2001;
Strathdee & Stockman, 2010).
Age and duration of injection use also correlates with co-infection.
The more time a PWID has been using drugs, the higher the risks of
HIV and HCV transmission. Unavailability of clean, unused syringes
has been found to be associated with HIV/HCV transmission (Woods,
Kerr, Motaner, et al., 2004; Pérez, Albizu-García, & Torres, 2015). In ad-
dition lack of awareness of themechanisms of HCV transmission and in
particular, its extreme transmissibility might have also played a role.
These risk factors also correlate with imprisonment, which has been
found to be a risk factor for HIV/HCV transmission as well (Deren,
Gelpí-Acosta, Albizu-García, et al., 2014).
Our data suggests that access to medical care correlates with co-in-
fection but this might not be a causal relationship. Since co-infected
PWID are covered by the equivalent to Medicare/Medicaid in PR while
those only affected by HCV are not, it is not surprising that co-infected
patients report a higher medical coverage than those that are not.
While 82.5% of our sample has state sponsored health insurance cover-
age, many are unable to access HCV treatment, as the state health insur-
ance plan will not cover this expensive treatment unless the patient is
also HIV positive. Barriers to HCV treatment in the island affects the
vast majority of HCV patients who will carry the virus for many years
(McCabe, Bostwick, West, & Boyd, 2010).
In turn, the fact that those co-infected tend to avoid sharing syringes
and drug equipment in a higher frequency than those that are not, is ex-
plained by their need to avoid transmittingHIV/HCV virus to their injec-
tion partners.
Sexual identity has been found to strongly correlate with HIV/HCV
co-infection. Those users self-identified as gay, lesbian, or transgender
have a much higher chance of being co-infected than those that de-
clared theywere heterosexual and gender conforming.We have to con-
sider the possibility that in a small sample of co-infected (n= 19) a few
cases can produce a biased result. Yet, there is a strong case to be made
that gay/lesbian and transgender PWID aremore vulnerable to co-infec-
tion. LGBT populations have higher rates of injection drug use than het-
erosexuals (Conron, Mimiaga, & Landers, 2010; De Santis, 2009).
Engaging in survival or commercial sex, or the exchange of sex for
drugs alongwith riskier sexual practices places this population at higher
risk for co-infection. Stigma, discrimination and violence compounds
co-infection risk (Deacon, Mooney-Somers, Treolar, & Maher, 2013;
Lombardi & Servellen van, 2000). Culturally sensitive prevention strate-
gies focused on this particular population should be implemented to
avoid co-infection [Perez, Marrero, Melendez, et al., 2010]. Yet, the
most pressing heath care problem is presented not by those that are
co-infected, which are a minority in our sample and whose access to
care is ensured in Puerto Rico, but those that tested reactive to HCV
and whose treatment is not provided unless they have access to private
insurance which is unlikely given their socio-economic status. HCV
among PWID in Puerto Rico has reached epidemic levels and if left un-
treated, it can have catastrophic effects not only in this group but its re-
lated health care costs associatedmight drain an already strained health
care system.
4.1. Study limitations
One of the limitations of this study is that HIV and HCV testing was
designed to identify the presence of virus but it did not measure viral
load or in the case of HCV genotyping. As a result, we are able to docu-
ment positive or reactive results but we are not able to measure where
the participant had been successfully treated. Another limitation arises
from the relatively small sample size of HIV/HCV co-infected PWID.
While our overall sample size (N = 315) is robust, a sub-set of (n =
19) co-infected participants raises problems of statistical significance.
Given the disparity between HIV and HCV prevalence among PWID,
we believe that this problem will be present in similar studies and we
stand behind the validity of our data.
5. Conclusion
While HCV and HIV co-infection is a serious public health issue, af-
fectingmillions of patients worldwide, with a strong prevalence of peo-
ple who inject drugs (PWID) in Western Europe and the United States,
little is known about social and behavioral determinants of HIV andHCV
co-infection amongPWID. Understanding the social determinants of co-
Table 1
HIV/HCV co-infection.
HIV/HCV
co-infected
Not
co-infected
Mean age 49.0⁎⁎⁎ 41.3⁎⁎⁎ N = 315
Mean # years injecting 29.1⁎⁎⁎ 19.3⁎⁎⁎ N = 315
% Gay, lesbian, or bisexual 21.5%⁎⁎⁎ 2.7%⁎⁎⁎ N = 314
% Men 89.5% 90.5% N = 315
Avg. per capita income $4591 $4443 N = 242
% Graduated HS or higher 52.6% 52.3% N = 315
% Born in Puerto Rico 93.9% 84.2% N = 314
% Homeless past year 38.6% 36.8% N = 315
% Currently homeless 26.3%⁎⁎ 21.6% N = 315
% Unemployed 89.5% 85.7% N = 312
% Have health insurance 100.0%⁎⁎⁎ 81.4%⁎⁎⁎ N = 315
% Have regular place for
healthcare
63.2%† 41.4%† N = 315
How often use new sterile
needle
4.2⁎ 3.6⁎ N = 315
† p b 0.10
⁎ p b 0.05
⁎⁎ p b 0.01
⁎⁎⁎ p b 0.001
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infection is critical in order to developmore effective prevention strate-
gies. By outlining the factors that lead to co-infection, this paper contrib-
utes to identify the behaviors or risk profiles that need to be addressed
to prevent the further spread of HCV among PWID in Puerto Rico and
abroad.
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